GLP-1 pen injection tutorials: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption "How to use GLP-1 pen" alongside Mounjaro hashtags, this video is almost certainly walking viewers through the physical mechanics of self-injecting a GLP-1 receptor agonist, likely tirzepatide (Mounjaro). That means demonstrating site selection, needle insertion angle, dialing a dose, or priming the pen. The Myanmar and Yangon hashtags suggest the creator is based in Southeast Asia, which raises immediate questions about the regulatory and supply chain context surrounding whatever product appears on screen. Given that Mounjaro has extremely limited official distribution in Myanmar, what's being injected, and from where it was sourced, are not trivial questions. Injection tutorial content has exploded on TikTok, and while some is genuinely helpful, a lot of it conflates different products, skips contraindication checks, and presents single-use pens as interchangeable with vials and syringes.

What does the science actually show?

Tirzepatide, the active ingredient in Mounjaro, is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on 15mg tirzepatide lost an average of 20.9% of body weight over 72 weeks. That's a real and significant effect, but it came with a structured titration schedule starting at 2.5mg weekly, escalating every four weeks. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) confirmed that stopping the drug leads to substantial weight regain, with participants regaining about two-thirds of lost weight within a year of discontinuation. Proper injection technique matters clinically. Subcutaneous administration into the abdomen, thigh, or upper arm is standard, with rotation between sites to prevent lipohypertrophy. Absorption rates do vary modestly by site, though tirzepatide's long half-life of approximately five days makes this less critical than with shorter-acting agents.

Where does the social media noise diverge from clinical reality?

Several patterns show up repeatedly in GLP-1 injection tutorials that range from sloppy to genuinely dangerous. First, many creators don't distinguish between different products. Semaglutide pens (Ozempic, Wegovy) and tirzepatide pens (Mounjaro, Zepbound) are not operated identically, and dose dials work differently across devices. Second, the titration schedule almost never gets adequate attention. Starting too high dramatically increases nausea, vomiting, and gastroparesis risk. The FDA label for Mounjaro is explicit: 2.5mg for four weeks before any increase. Third, tutorial creators in markets with limited official supply are often working with grey-market or compounded products that may not match the physical pen design being demonstrated. That's a meaningful gap. Compounded tirzepatide is not FDA-approved, and its concentration, sterility, and excipient profile differ from the branded product. Treating injection tutorials as universal instructions across products is a real patient safety problem.

What should you actually know?

If you're using a GLP-1 medication, the injection mechanics are genuinely learnable, but they need to come from your prescribing clinician or pharmacist, not a TikTok tutorial filmed in a different regulatory environment with a product you can't verify. A few things that actually matter: always check the pen is not expired or cloudy, rotate injection sites to prevent localized tissue changes, inject at room temperature to reduce injection site pain, and never share a pen device even if you change the needle. The SCALE trial program for liraglutide and the SUSTAIN program for semaglutide both documented that injection site reactions are more common when technique is poor. If you're experiencing persistent nausea, you may be on too high a dose too fast, not using bad technique. That's a conversation for a clinician, not a comment section. FormBlends-connected prescribers follow FDA-compliant titration schedules precisely because the clinical data is clear that slower escalation improves tolerability without sacrificing long-term outcomes.